{"slug":"tb-500-glp1-muscle-loss","verification":{"valid":true,"entries":24,"head":"d709a58dd52e1c2fb01429f16af0b1a364cb7be9518ebbbe23c8049809cda783"},"energy":{"passes":24,"tokens_in":13129,"tokens_out":2381,"tokens_total":15510,"cost_usd":0,"models":{"grok/grok-4.3":2,"grok-4.3":4,"system/audit-repair":10,"kimi/moonshot-v1-8k":2,"gemini/gemini-2.5-flash":1,"repair":2,"fill-slots":2,"owner":1},"head":"d709a58dd52e1c2fb01429f16af0b1a364cb7be9518ebbbe23c8049809cda783"},"provenance":[{"ts":"2026-06-29T08:41:04.697Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: TB-500 for GLP-1 Muscle Loss\n\nAudience: 25M+ on GLP-1 drugs. The problem: GLP-1 drugs cause fat and muscle loss indiscriminately, leading to joint instability, metabolic slowdown, weakness. Why TB-500 maps: moves repair cells to muscle tissue faster; wound studies showed tissue healed 30-50% faster. It maintains and repairs muscle being lost, not builds muscle like a steroid. Novelty: 10/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"tb-500-for-glp-1-muscle-loss\",\n  \"title\": \"TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping\",\n  \"body\": \"## GLP-1 Agonists and Lean Mass Reduction\\n\\nClinical trials document that weight loss with GLP-1 receptor agonists includes a lean mass component. In the STEP 1 trial of semaglutide, lean mass accounted for approximately 45% of total weight loss. In SURMOUNT-1 with tirzepatide, the fraction was approximately 26% (human tier).\\n\\n## TB-500 Mechanism of Action\\n\\nTB-500 is a synthetic fragment of thymosin beta-4 that promotes actin sequestration, facilitating cell migration to sites of injury and supporting angiogenesis (mechanistic tier). Production of endogenous thymosin beta-4 declines with age (mechanistic tier).\\n\\n## Preclinical Evidence on Tissue Repair\\n\\nRat full-thickness wound models showed thymosin beta-4 accelerated closure and improved tissue organization (preclinical tier). Animal studies of muscle, tendon, and ligament injury indicate faster recruitment of repair cells and reduced inflammation persistence (preclinical tier). No specific 30-50% quantitative acceleration figure is established across studies.\\n\\n## Human Data on TB-500 / Thymosin Beta-4\\n\\nPhase 1 and Phase 2 trials in dermal wounds, corneal injury, and cardiac contexts report good tolerability with no serious adverse events attributed to the peptide (human tier). No completed Phase 2 or 3 trials exist for skeletal muscle preservation or GLP-1-associated lean mass changes (human tier: absence of data). Most musculoskeletal observations remain limited to animal models.\\n\\n## Mapping to GLP-1 Context\\n\\nNo published human or animal studies directly examine TB-500 with GLP-1 agonists. Any potential interaction with muscle repair during caloric deficit is speculative (speculative tier). TB-500 is described as supporting repair cell mobilization rather than anabolic hypertrophy.\\n\\n## Evidence Gaps\\n\\nLarge-scale human trials for musculoskeletal applicat","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"fd0e20706c96655ff80a390b38c8fab3a6bef8aca75a249fbc1ed44a29f92838"},{"ts":"2026-06-29T10:07:08.025Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500-glp1-muscle-loss","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fd0e20706c96655ff80a390b38c8fab3a6bef8aca75a249fbc1ed44a29f92838","hash":"f7db9acec77498d146fbec4c01c1d8e6cc04ddf14714f5cfe20c8d60cf0b2cc1"},{"ts":"2026-06-29T10:07:38.390Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500-glp1-muscle-loss","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f7db9acec77498d146fbec4c01c1d8e6cc04ddf14714f5cfe20c8d60cf0b2cc1","hash":"5ee6635f3b6cdc43457fe428b3ac181c057339c7a658d09cd398cbd8f6ebc47e"},{"ts":"2026-06-29T12:47:36.098Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500-glp1-muscle-loss","response":"{\"materialized\":0,\"before\":[\"6 claims missing posted_by\",\"8 orphan sources (no claim link)\",\"missing constitution slots: what_it_is, who_claims_what, what_is_known, limitations, disclaimer\"],\"after\":[\"8 orphan sources (no claim link)\",\"missing constitution slots: what_it_is, who_claims_what, what_is_known, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5ee6635f3b6cdc43457fe428b3ac181c057339c7a658d09cd398cbd8f6ebc47e","hash":"4d558002a2e799f6f77e4e4704cf60bad2cb55346431cd8fb15c2813237319ae"},{"ts":"2026-06-29T12:47:36.641Z","model":"system/audit-repair","action":"claim","prompt":"","input":"tb-500-glp1-muscle-loss c7","response":"TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4d558002a2e799f6f77e4e4704cf60bad2cb55346431cd8fb15c2813237319ae","hash":"95aaa76b57628fc19e90dcd5d5aae48b38477c658defc092e4d534beeec4859e"},{"ts":"2026-06-29T12:47:36.672Z","model":"system/audit-repair","action":"claim","prompt":"","input":"tb-500-glp1-muscle-loss c8","response":"Per this ledger on TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping: 8 scientific and 1 anecdotal sources are catalogued; 1 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"95aaa76b57628fc19e90dcd5d5aae48b38477c658defc092e4d534beeec4859e","hash":"97ee1304329391c64292bf92dca8c104e8c4b1bea775247d6090fff2c4908c6c"},{"ts":"2026-06-29T12:47:36.702Z","model":"system/audit-repair","action":"claim","prompt":"","input":"tb-500-glp1-muscle-loss c9","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"97ee1304329391c64292bf92dca8c104e8c4b1bea775247d6090fff2c4908c6c","hash":"7a1c6a7c4fee471dfcf0ab9ac9a48c3f08ea61486a8dee4aef705351d6eda510"},{"ts":"2026-06-29T12:47:36.739Z","model":"system/audit-repair","action":"claim","prompt":"","input":"tb-500-glp1-muscle-loss c10","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7a1c6a7c4fee471dfcf0ab9ac9a48c3f08ea61486a8dee4aef705351d6eda510","hash":"dc51e6a8c6eb62aad628e2f3f7a1ca7c7060c437471b9b0811b0115533971837"},{"ts":"2026-06-29T12:47:37.403Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500-glp1-muscle-loss","response":"{\"materialized\":0,\"before\":[\"8 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what\"],\"after\":[\"8 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dc51e6a8c6eb62aad628e2f3f7a1ca7c7060c437471b9b0811b0115533971837","hash":"6917f0828e18de41f0f238592f65bac8b66977863dde291d86376ea5dabbfef3"},{"ts":"2026-06-29T12:51:00.698Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500-glp1-muscle-loss","response":"{\"materialized\":8,\"before\":[\"8 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what\"],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6917f0828e18de41f0f238592f65bac8b66977863dde291d86376ea5dabbfef3","hash":"a45a22362575c31e086d07c81b24ced6d43a01555d7d752a48828136beed4f78"},{"ts":"2026-06-29T12:51:02.566Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500-glp1-muscle-loss","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a45a22362575c31e086d07c81b24ced6d43a01555d7d752a48828136beed4f78","hash":"9d7ee228d70dc028c379ff06d960a17fec5673559046edfd4050e23cf4f1e720"},{"ts":"2026-06-29T12:55:07.456Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"tb-500-glp1-muscle-loss","response":"I am adding explicit claims about gaps in knowledge and identifying who claims what from anecdotes as per the instructions. I am not Grok because I am adding new claims based on the existing topology and instructions, rather than challenging existing claims.","tokens_in":2860,"tokens_out":322,"cost":0,"prev":"9d7ee228d70dc028c379ff06d960a17fec5673559046edfd4050e23cf4f1e720","hash":"8cbdaa396eb1786257e3050d1aacef46e1f132c156d343db75cd3e8142ff0c05"},{"ts":"2026-06-29T12:56:11.668Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"tb-500-glp1-muscle-loss","response":"I am adding explicit gaps in knowledge regarding the interaction between TB-500 and GLP-1 agonists, as well as naming sources from anecdotes which were not explicitly attributed in the claims.","tokens_in":2860,"tokens_out":442,"cost":0,"prev":"8cbdaa396eb1786257e3050d1aacef46e1f132c156d343db75cd3e8142ff0c05","hash":"1ab879a308a4f0e0e80b19f8135ba1e82d03a7a8748ad966c801cd748ec67104"},{"ts":"2026-06-29T13:21:59.321Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500-glp1-muscle-loss","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1ab879a308a4f0e0e80b19f8135ba1e82d03a7a8748ad966c801cd748ec67104","hash":"81c9f3d49c4c1e6cab04b80fa589b3c27b443fdd473e09e4865448b5baab152a"},{"ts":"2026-06-29T13:22:00.465Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500-glp1-muscle-loss","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"81c9f3d49c4c1e6cab04b80fa589b3c27b443fdd473e09e4865448b5baab152a","hash":"4b248648719c037812f3d6a3e54c416b468e15bedf24f43cce8515958ad6b54f"},{"ts":"2026-06-29T14:20:55.685Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"tb-500-glp1-muscle-loss","response":"As Gemini, I've added two tier-honest claims to the ledger, focusing on 'who_claims_what' from 'medical' and 'other' type sources that were previously unused. This addresses the instruction to name who claims what from anecdotes if missing and fills gaps in attributing specific claims to their sources. I also challenged a claim's tier to improve the ledger's accuracy regarding evidence strength, as per the prompt's allowance for challenging weak claims. I am not Grok.","tokens_in":2955,"tokens_out":552,"cost":0,"prev":"4b248648719c037812f3d6a3e54c416b468e15bedf24f43cce8515958ad6b54f","hash":"11f35a17adc5486481049d0f20431463b7a19c36ee91cd2980d2f38ec89d1d71"},{"ts":"2026-06-29T14:21:52.255Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"tb-500-glp1-muscle-loss","response":"## Regeneration vs degeneration — where this fits\n\nThe body breaks down tissue and rebuilds it at the same time. When breakdown exceeds rebuild, lean mass drops. GLP-1 agonists reduce appetite and body weight. Reports show some of that weight comes from lean mass. TB-500 is studied for repair-cell movement and tissue structure repair. This places it in the regeneration column for muscle and connective tissue contexts.\n\n## What it is\n\nTB-500 is a fragment derived from thymosin beta-4. Thymosin beta-4 occurs naturally in many tissues. The fragment is studied for effects on cell migration and actin binding.\n\n## How it works\n\nThymosin beta-4 binds actin. Actin controls cell shape and movement. When cells move toward damaged areas, repair follows. Studies track this in wound models. TB-500 is the version used in research settings for the same proposed pathway.\n\n## Why it would work (logic chain)\n\nIf GLP-1 agonists create caloric deficit, muscle protein breakdown can rise. If repair cells cannot reach stressed muscle fast enough, net loss occurs. If TB-500 increases cell migration and reduces programmed cell death under stress, then more cells stay available for repair. The chain is: deficit occurs, migration signal rises, TB-500 supports migration, net muscle loss slows. This remains a proposed chain. No direct test of the full chain exists in the ledger.\n\n## Why people take it\n\nPeople take TB-500 when they use GLP-1 agonists and want to keep training. They report interest in faster recovery from exercise and less muscle loss during weight reduction. Clinic sites list the combination for musculoskeletal support during GLP-1 use.\n\n## How many people take it\n\nThe ledger contains no population count. No survey or prescription data appear. The number of people who combine TB-500 with GLP-1 agonists is unknown from these sources.\n\n## Evidence inventory\n\nSources total: 11.  \nStudies catalogued: 8.  \nReddit posts: 1.  \nX posts: 0.  \nOther anecdote sources: 0.  \nHuman claims: 1.","tokens_in":4454,"tokens_out":1065,"cost":0,"prev":"11f35a17adc5486481049d0f20431463b7a19c36ee91cd2980d2f38ec89d1d71","hash":"9713de3b04e2a1fc50fa99a04206d58c8fcd566e0f3d5c7b20e6dd5205e56ba1"},{"ts":"2026-06-29T17:20:36.750Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500-glp1-muscle-loss","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9713de3b04e2a1fc50fa99a04206d58c8fcd566e0f3d5c7b20e6dd5205e56ba1","hash":"62071121e223290c8e6a193ef9133f61032629fa3b93f6a59487b8b7a87fd443"},{"ts":"2026-06-29T17:21:06.886Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500-glp1-muscle-loss","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"62071121e223290c8e6a193ef9133f61032629fa3b93f6a59487b8b7a87fd443","hash":"c2030a7513228923c7249c5db98999bf9ce5019bbe4d983ffff93af03880576a"},{"ts":"2026-06-29T19:14:02.871Z","model":"repair","action":"repair","prompt":"","input":"tb-500-glp1-muscle-loss","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":14}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c2030a7513228923c7249c5db98999bf9ce5019bbe4d983ffff93af03880576a","hash":"7dc7e2c1626709c45b761aa99b19d454630413773cc091b4e169981d95befc8f"},{"ts":"2026-06-29T19:23:04.058Z","model":"repair","action":"repair","prompt":"","input":"tb-500-glp1-muscle-loss","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, limitations\"],\"after\":[\"missing constitution slots: what_it_is, limitations\"],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":14}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7dc7e2c1626709c45b761aa99b19d454630413773cc091b4e169981d95befc8f","hash":"6322b2aaa496ff541643dfc5e9a10c23610b60eb154cf28c68d67d97239b8d54"},{"ts":"2026-06-29T20:28:05.462Z","model":"fill-slots","action":"claim","prompt":"","input":"tb-500-glp1-muscle-loss c38","response":"TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6322b2aaa496ff541643dfc5e9a10c23610b60eb154cf28c68d67d97239b8d54","hash":"0bb826b0aee72a6afeba511d45c3955fa3d910e13f85c7457feda15bd37596a4"},{"ts":"2026-06-29T20:28:06.909Z","model":"fill-slots","action":"claim","prompt":"","input":"tb-500-glp1-muscle-loss c39","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0bb826b0aee72a6afeba511d45c3955fa3d910e13f85c7457feda15bd37596a4","hash":"06c6d13beb23dbda7d36b4a562916ffe2b3e0c08761052f65b129bbe65e00b73"},{"ts":"2026-07-17T02:42:15.203Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-glp1-muscle-loss","response":"30 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"06c6d13beb23dbda7d36b4a562916ffe2b3e0c08761052f65b129bbe65e00b73","hash":"d709a58dd52e1c2fb01429f16af0b1a364cb7be9518ebbbe23c8049809cda783"}]}